Texas A&M Health Science Center, Rangel College of Pharmacy, Pharmaceutical Sciences, Kingsville, Texas 78363–8202, USA.
Issues Ment Health Nurs. 2012 Nov;33(11):797-800. doi: 10.3109/01612840.2012.698370.
A 55-year-old female with a diagnosis of schizophrenia currently resides in an assisted living facility in a large metropolitan suburb. For approximately 25 years, the patient was relegated to a life of poor symptom control and social adjustment, largely due to nonadherence, relapse, and rehospitalization. The patient experienced a trial-and-error approach to drug therapy, which resulted in reliance on the older or first generation agents for symptom improvement. This case supports the assertion that the second-generation or atypical antipsychotics used to treat schizophrenia are no better than older drugs in terms of efficacy or tolerability.
一位 55 岁的女性，被诊断患有精神分裂症，目前居住在一个大城市郊区的辅助生活设施中。大约 25 年来，由于不遵医嘱、复发和再次住院，该患者的症状控制和社会适应能力一直很差。该患者的药物治疗经历了一个反复试验的过程，这导致她依赖于较老的或第一代药物来改善症状。这个病例支持这样一种说法，即第二代或非典型抗精神病药物用于治疗精神分裂症在疗效或耐受性方面并不优于旧药物。
